MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412884 | Name: Piroxicam betadex

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Piroxicam betadex is a nonsteroidal anti-inflammatory drug. The mechanism of action of piroxicam is as a cyclooxygenase Inhibitor. It is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. It is used to reduce pain, swelling, and joint stiffness from arthritis. Reducing these symptoms helps you do more of your normal daily activities.

Chemical Structure

Piroxicam betadex
Piroxicam betadex
CAS#96684-40-1 (betadex)

Theoretical Analysis

MedKoo Cat#: 412884

Name: Piroxicam betadex

CAS#: 96684-40-1 (betadex)

Chemical Formula: C57H83N3O39S

Exact Mass:

Molecular Weight: 1466.33

Elemental Analysis: C, 46.69; H, 5.71; N, 2.87; O, 42.55; S, 2.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
87234-24-0 (cinnamate); 85056-47-9 (olamine); 36322-90-4 (free base); 96684-40-1 (betadex)
Synonym
Piroxicam betadex; Brexin; Cicladol
IUPAC/Chemical Name
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-,1,1-dioxide, compd with beta-cyclodextrin (2:5)
InChi Key
LBPBSKKEZXLVBQ-WZHIEOAOSA-N
InChi Code
InChI=1S/C42H70O35.C15H13N3O4S/c43-1-8-29-15(50)22(57)36(64-8)72-30-9(2-44)66-38(24(59)17(30)52)74-32-11(4-46)68-40(26(61)19(32)54)76-34-13(6-48)70-42(28(63)21(34)56)77-35-14(7-49)69-41(27(62)20(35)55)75-33-12(5-47)67-39(25(60)18(33)53)73-31-10(3-45)65-37(71-29)23(58)16(31)51;1-18-13(15(20)17-12-8-4-5-9-16-12)14(19)10-6-2-3-7-11(10)23(18,21)22/h8-63H,1-7H2;2-9,19H,1H3,(H,16,17,20)/t8-,9-,10-,11-,12-,13-,14-,15-,16-,17-,18-,19-,20-,21?,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-;/m1./s1
SMILES Code
CN1C(C(Nc2ncccc2)=O)=C(c3c(S1(=O)=O)cccc3)O.OC[C@H]4O[C@@H]5O[C@H]6[C@@H]([C@H]([C@@H](O[C@H]7[C@@H]([C@H]([C@@H](O[C@H]8C([C@H]([C@@H](O[C@H]9[C@@H]([C@H]([C@@H](O[C@H]%10[C@@H]([C@H]([C@@H](O[C@H]%11[C@@H]([C@H]([C@@H](O[C@H]4[C@@H]([C@H]5O)O)O[C@@H]%11CO)O)O)O[C@@H]%10CO)O)O)O[C@@H]9CO)O)O)O[C@@H]8CO)O)O)O[C@@H]7CO)O)O)O[C@@H]6CO)O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,466.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Piroxicam. 2018 Oct 31. PMID: 30000130. 2: Santos AM, Wong A, Vicentini FC, Fatibello-Filho O. Simultaneous voltammetric sensing of levodopa, piroxicam, ofloxacin and methocarbamol using a carbon paste electrode modified with graphite oxide and β-cyclodextrin. Mikrochim Acta. 2019 Feb 15;186(3):174. doi: 10.1007/s00604-019-3296-x. PMID: 30771008. 3: Umile A. Piroxicam-beta-cyclodextrin and photosensitivity reactions. Contact Dermatitis. 1999 Jun;40(6):340-2. doi: 10.1111/j.1600-0536.1999.tb06100.x. PMID: 10385352. 4: Woodcock BG, Acerbi D, Merz PG, Rietbrock S, Rietbrock N. Supermolecular inclusion of piroxicam with beta-cyclodextrin: pharmacokinetic properties in man. Eur J Rheumatol Inflamm. 1993;12(4):12-28. PMID: 7805700. 5: Deroubaix X, Stockis A, Allemon AM, Lebacq E, Acerbi D, Ventura P. Oral bioavailability of CHF1194, an inclusion complex of piroxicam and beta- cyclodextrin, in healthy subjects under single dose and steady-state conditions. Eur J Clin Pharmacol. 1995;47(6):531-6. doi: 10.1007/BF00193707. PMID: 7768257. 6: Varela P, Amorim I, Massa A, Sanches M, Silva E. Piroxicam-beta-cyclodextrin and photosensitivity reactions. Contact Dermatitis. 1998 Apr;38(4):229. doi: 10.1111/j.1600-0536.1998.tb05726.x. PMID: 9565309. 7: Warrington S, Debbas N, Farthing M, Horton M, Umile A. Piroxicam-beta- cyclodextrin: effects on gastrointestinal blood loss and gastric mucosal appearance in healthy men. Int J Tissue React. 1991;13(5):243-8. PMID: 1806546. 8: Lauretti GR, Mattos AL, Lima IC. Tramadol and beta-cyclodextrin piroxicam: effective multimodal balanced analgesia for the intra- and postoperative period. Reg Anesth. 1997 May-Jun;22(3):243-8. doi: 10.1016/s1098-7339(06)80009-x. PMID: 9168216. 9: Dalmora ME, Dalmora SL, Oliveira AG. Inclusion complex of piroxicam with beta-cyclodextrin and incorporation in cationic microemulsion. In vitro drug release and in vivo topical anti-inflammatory effect. Int J Pharm. 2001 Jul 3;222(1):45-55. doi: 10.1016/s0378-5173(01)00692-5. PMID: 11404031. 10: Trucco M, Antonaci F, Sandrini G. Hemicrania continua: a case responsive to piroxicam-beta-cyclodextrin. Headache. 1992 Jan;32(1):39-40. doi: 10.1111/j.1526-4610.1992.hed3201039.x. PMID: 1555930.